Holen Sie sich die Stockscreener-App
4.70
5.05%
-0.25
Handel nachbörslich:
4.69
-0.010
-0.21%
Schlusskurs vom Vortag:
$4.95
Offen:
$4.99
24-Stunden-Volumen:
774.11K
Relative Volume:
0.48
Marktkapitalisierung:
$328.11M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-297.11M
KGV:
-0.9056
EPS:
-5.19
Netto-Cashflow:
$-216.95M
1W Leistung:
+15.20%
1M Leistung:
+70.29%
6M Leistung:
-47.49%
1J Leistung:
-54.63%
1-Tages-Spanne:
$4.615
$4.99
1-Wochen-Bereich:
$4.05
$4.99
52-Wochen-Spanne:
$2.21
$19.71
Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile
Firmenname
Phathom Pharmaceuticals Inc
Sektor
Branche
Telefon
(877) 742-8466
Adresse
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
Vergleichen Sie PHAT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PHAT
Phathom Pharmaceuticals Inc
|
4.70 | 284.84M | 0 | -297.11M | -216.95M | -5.19 |
|
ONC
Beone Medicines Ltd Adr
|
258.27 | 26.01B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.85 | 114.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.3499 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
83.98 | 6.29B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
484.93 | 63.90B | 14.09B | 4.50B | 2.96B | 39.28 |
Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-05-03 | Eingeleitet | Stifel | Buy |
| 2024-01-05 | Bestätigt | Needham | Buy |
| 2023-08-09 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-05-11 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-03-13 | Eingeleitet | Craig Hallum | Buy |
| 2022-10-21 | Eingeleitet | Jefferies | Buy |
| 2022-05-06 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2021-05-12 | Hochstufung | Goldman | Sell → Neutral |
| 2021-02-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-02-02 | Eingeleitet | Guggenheim | Buy |
| 2020-06-26 | Herabstufung | Goldman | Neutral → Sell |
| 2019-11-20 | Eingeleitet | Evercore ISI | Outperform |
| 2019-11-19 | Eingeleitet | Goldman | Neutral |
| 2019-11-19 | Eingeleitet | Jefferies | Buy |
| 2019-11-19 | Eingeleitet | Needham | Buy |
Alle ansehen
Phathom Pharmaceuticals Inc Aktie (PHAT) Neueste Nachrichten
ProShare Advisors LLC Has $116,000 Stock Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
Investors Still Aren't Entirely Convinced By Phathom Pharmaceuticals, Inc.'s (NASDAQ:PHAT) Revenues Despite 54% Price Jump - simplywall.st
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Raises Stake in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
Deutsche Bank AG Increases Stock Holdings in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
Brokerages Set Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) PT at $17.60 - Defense World
BNP Paribas Financial Markets Purchases Shares of 39,532 Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
Northern Trust Corp Has $3.23 Million Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
Even after rising 39% this past week, Phathom Pharmaceuticals (NASDAQ:PHAT) shareholders are still down 89% over the past five years - simplywall.st
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewswire
GI Disease Leader Phathom to Present at 3 Elite Healthcare Conferences: Goldman Sachs, Jefferies, H.C. Wainwright - Stock Titan
(PHAT) Proactive Strategies - news.stocktradersdaily.com
Phathom pharmaceuticals outlines VOQUEZNA expansion targets and cost-saving measures for profitability by 2026 - MSN
After Plunging -45.82% in 4 Weeks, Here's Why the Trend Might Reverse for Phathom Pharmaceuticals (PHAT) - MSN
Phathom Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:PHAT) - Defense World
Phathom Pharmaceuticals surges 50% following large insider purchase - MSN
Phathom Pharmaceuticals (PHAT) Shares Surge After Board Member's Large Purchase - GuruFocus
Wells Fargo & Company MN Raises Stock Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
Insider Buying: Asit Parikh Acquires Additional Shares of Phathom Pharmaceuticals Inc (PHAT) - GuruFocus
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Shares Acquired by Barclays PLC - Defense World
Finance Watch: Unity Lays Off All Employees As It Evaluates Alternatives - insights.citeline.com
HC Wainwright Cuts Phathom Pharmaceuticals (NASDAQ:PHAT) Price Target to $20.00 - Defense World
Retail Interest in Phathom Soars As Firm Pledges Profit Path, Cuts Costs After Q1 Miss - MSN
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Just Reported, And Analysts Assigned A US$18.63 Price Target - Yahoo Finance
The Goldman Sachs Group Issues Pessimistic Forecast for Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price - Defense World
Phathom Pharmaceuticals First Quarter 2025 Earnings: Misses Expectations - Yahoo
H.C. Wainwright cuts Phathom Pharma stock target to $20, keeps Buy rating - Investing.com Canada
Phathom Pharmaceuticals (PHAT) Price Target Lowered by Goldman S - GuruFocus
Phathom Pharmaceuticals (PHAT) Target Price Lowered by Guggenhei - GuruFocus
Phathom Pharmaceuticals (PHAT) Maintains Buy Rating as Price Tar - GuruFocus
Phathom Pharmaceuticals (PHAT) Maintains Buy Rating as Price Target Drops | PHAT Stock News - GuruFocus
Phathom Pharmaceuticals (PHAT) Price Target Reduced by Guggenhei - GuruFocus
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q1 2025 Earnings Call Transcript - Insider Monkey
Phathom Pharmaceuticals (PHAT) Price Target Reduced by Guggenheim | PHAT Stock News - GuruFocus
PHAT Faces Price Target Cut Amidst Restructuring Efforts | PHAT Stock News - GuruFocus
Phathom Pharmaceuticals Inc (PHAT) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... - Yahoo Finance
Phathom Pharmaceuticals Inc (PHAT) Q1 2025 Earnings Call Highlig - GuruFocus
Phathom Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks
Phathom Pharmaceuticals Eyes Profitability Amid Growth - TipRanks
Phathom Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | PHAT Stock News - GuruFocus
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Phathom Pharmaceuticals Grants 186,508 Shares Package to New Sales Chief in Strategic Hire - Stock Titan
Phathom (PHAT) Implements Strategic Shift for Long-Term Growth | - GuruFocus
Phathom Pharmaceuticals Q1 2025 Earnings: EPS Matches Estimates at -$1.18, Revenue Falls Short at $28.5 Million - GuruFocus
Arvinas ends plans for two Phase 3 breast cancer trials; Phathom makes cuts - Endpoints News
Phathom Pharmaceuticals stock hits 52-week low at $3.8 By Investing.com - Investing.com India
Phathom Pharmaceuticals to Report First Quarter 2025 Financial R - GuruFocus
Phathom Pharmaceuticals stock hits 52-week low at $3.8 - Investing.com
Earnings call transcript: Phathom Pharmaceuticals beats Q1 2025 earnings expectations - Investing.com
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Finanzdaten der Phathom Pharmaceuticals Inc-Aktie (PHAT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.00%
0.54%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):